Home Topics Cancer Epizyme Charts Five-Year Clinical Vision, Seeing Silver Linings Amid Tazverik Clouds

Epizyme TAZVERIK CROPPED11111 — Despite first-year sales that missed analyst forecasts for its first marketed drug TAZVERIK® (tazemetostat), Epizyme says encouraging fourth quarter trends point to a better 2021 for the cancer drug. The company recently detailed its development strategy and pipeline priorities over the next five years during a “Strategic Vision Call.” [Epizyme]

Epizyme Charts Five-Year Clinical Vision, Seeing Silver Linings Amid Tazverik Clouds

By Alex Philippidis

April 5, 2021

Despite first-year sales that missed analyst forecasts for its first marketed drug TAZVERIK^®(tazemetostat), Epizyme says encouraging fourth quarter trends point to a better 2021 for the cancer drug. The company recently detailed its development strategy and pipeline priorities over the next five years during a “Strategic Vision Call.” [Epizyme]

Epizyme recently detailed its development strategy and pipeline priorities over the next five years during a “Strategic Vision Call.” Those priorities include launching two signal-finding “basket” studies in the second half of 2021 to evaluate tazemetostat safety and efficacy across multiple new types of blood and solid tumors; and advancing to the clinic its SETD2 inhibitor program . . .